Clinical Trial Update: PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of pegylated liposomal doxorubicin (PLD) with cisplatin for advanced poorly differentiated thyroid carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Poorly Differentiated Thyroid Carcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Pegylated liposomal doxorubicin (pegylated liposomal doxorubicin)

Snippet

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Conditions: Poorly Differentiated Thyroid Carcinoma | Phase 2 | Status: UNKNOWN